200 related articles for article (PubMed ID: 26914556)
1. PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?
Taywade SK; Damle NA; Bal C
Clin Nucl Med; 2016 May; 41(5):e263-5. PubMed ID: 26914556
[TBL] [Abstract][Full Text] [Related]
2. The prostate-specific membrane antigen (PSMA)-targeted radiotracer
Santhanam P; Russell J; Rooper LM; Ladenson PW; Pomper MG; Rowe SP
Med Oncol; 2020 Oct; 37(11):98. PubMed ID: 33034761
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Meshram V; Chandak A; Sonavane S; Lila AR; Bandgar TR; Asopa RV
Clin Nucl Med; 2021 Aug; 46(8):e406-e409. PubMed ID: 33883490
[TBL] [Abstract][Full Text] [Related]
4. More than the prostate: Intrapancreatic accessory spleen and papillary thyroid cancer detected with
Singh D; Horneman R; Nagra NK
Hell J Nucl Med; 2018; 21(2):145-147. PubMed ID: 30006647
[TBL] [Abstract][Full Text] [Related]
5. 68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
Einspieler I; Tauber R; Maurer T; Schwaiger M; Eiber M
Clin Nucl Med; 2016 May; 41(5):e261-2. PubMed ID: 26859205
[TBL] [Abstract][Full Text] [Related]
6. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV
Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335
[TBL] [Abstract][Full Text] [Related]
7. Axillary lymph node metastasis of papillary thyroid carcinoma detected by FDG PET/CT in a thyroglobulin-positive patient with negative whole-body 131I scan.
Elboga U; Kalender E; Yilmaz M; Celen YZ; Aktolun C
Clin Nucl Med; 2012 Nov; 37(11):1120-2. PubMed ID: 22996245
[TBL] [Abstract][Full Text] [Related]
8. Brain-Only Metastases Seen on FDG PET as First Relapse of Papillary Thyroid Carcinoma Two Years Post-Thyroidectomy.
Naddaf SY; Syed GM; Hadb A; Al-Thaqfi S
Clin Nucl Med; 2016 Sep; 41(9):693-4. PubMed ID: 27405041
[TBL] [Abstract][Full Text] [Related]
9. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
10. Asymptomatic solitary cerebral metastasis from papillary carcinoma thyroid: 131I SPECT/CT for accurate staging.
Jain TK; Karunanithi S; Sharma P; Vijay MK; Ballal S; Bal C
Clin Nucl Med; 2014 Nov; 39(11):977-9. PubMed ID: 24566406
[TBL] [Abstract][Full Text] [Related]
11. Head-to-Head Comparison of
Pitalua-Cortes Q; García-Perez FO; Vargas-Ahumada J; Gonzalez-Rueda S; Gomez-Argumosa E; Ignacio-Alvarez E; Soldevilla-Gallardo I; Torres-Agredo L
Front Endocrinol (Lausanne); 2021; 12():794759. PubMed ID: 35002972
[TBL] [Abstract][Full Text] [Related]
12. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
13. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
14. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
15. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
[TBL] [Abstract][Full Text] [Related]
16. Widespread Metastatic Prostate Carcinoma Shown by 68Ga-PSMA PET/CT.
Soydal C; Ozkan E; Yerlikaya H; Utkan G; Kucuk ON
Clin Nucl Med; 2016 Jun; 41(6):e294-5. PubMed ID: 26909710
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
[TBL] [Abstract][Full Text] [Related]
18. Recurrent Medullary Thyroid Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT: Exploring New Theranostic Avenues.
Arora S; Damle NA; Parida GK; Singhal A; Nalli H; Dattagupta S; Bal C
Clin Nucl Med; 2018 May; 43(5):359-360. PubMed ID: 29485449
[TBL] [Abstract][Full Text] [Related]
19. PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT.
Derlin T; Kreipe HH; Schumacher U; Soudah B
Clin Nucl Med; 2017 Mar; 42(3):e173-e174. PubMed ID: 27997422
[TBL] [Abstract][Full Text] [Related]
20.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
